KR101700229B1 - 화합물들 - Google Patents

화합물들 Download PDF

Info

Publication number
KR101700229B1
KR101700229B1 KR1020117024068A KR20117024068A KR101700229B1 KR 101700229 B1 KR101700229 B1 KR 101700229B1 KR 1020117024068 A KR1020117024068 A KR 1020117024068A KR 20117024068 A KR20117024068 A KR 20117024068A KR 101700229 B1 KR101700229 B1 KR 101700229B1
Authority
KR
South Korea
Prior art keywords
alkyl
optionally substituted
aryl
heterocycloalkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117024068A
Other languages
English (en)
Korean (ko)
Other versions
KR20110128925A (ko
Inventor
에드워드 질스 맥이버
엘라 스밀랴니치
데니스 자밀라 하딩
조엔 허프
Original Assignee
메디칼 리서치 카운실 테크놀로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0904746A external-priority patent/GB0904746D0/en
Priority claimed from GB0912238A external-priority patent/GB0912238D0/en
Priority claimed from GBGB1001418.1A external-priority patent/GB201001418D0/en
Application filed by 메디칼 리서치 카운실 테크놀로지 filed Critical 메디칼 리서치 카운실 테크놀로지
Publication of KR20110128925A publication Critical patent/KR20110128925A/ko
Application granted granted Critical
Publication of KR101700229B1 publication Critical patent/KR101700229B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65611—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system (X = CH2, O, S, NH) optionally with an additional double bond and/or substituents, e.g. penicillins and analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117024068A 2009-03-19 2010-03-19 화합물들 Expired - Fee Related KR101700229B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0904746.5 2009-03-19
GB0904746A GB0904746D0 (en) 2009-03-19 2009-03-19 Compounds
US16202409P 2009-03-20 2009-03-20
US61/162,024 2009-03-20
GB0912238A GB0912238D0 (en) 2009-07-14 2009-07-14 Compounds
GB0912238.3 2009-07-14
GB1001418.1 2010-01-28
GBGB1001418.1A GB201001418D0 (en) 2010-01-28 2010-01-28 Compounds
PCT/GB2010/000498 WO2010106333A1 (en) 2009-03-19 2010-03-19 Compounds

Publications (2)

Publication Number Publication Date
KR20110128925A KR20110128925A (ko) 2011-11-30
KR101700229B1 true KR101700229B1 (ko) 2017-01-26

Family

ID=42226628

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117024068A Expired - Fee Related KR101700229B1 (ko) 2009-03-19 2010-03-19 화합물들

Country Status (13)

Country Link
US (2) US20100317646A1 (https=)
EP (1) EP2408772B1 (https=)
JP (1) JP5732036B2 (https=)
KR (1) KR101700229B1 (https=)
CN (1) CN102428084B (https=)
AU (1) AU2010224693B2 (https=)
CA (1) CA2754605C (https=)
CL (1) CL2011002267A1 (https=)
IL (1) IL215147A0 (https=)
MX (1) MX2011009807A (https=)
PE (1) PE20120506A1 (https=)
RU (1) RU2011142182A (https=)
WO (1) WO2010106333A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2658984C (en) * 2006-08-16 2014-12-02 Joshua Kennedy-Smith Non-nucleoside reverse transcriptase inhibitors
GB201008134D0 (en) * 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
GB201015949D0 (en) * 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
US9233977B2 (en) * 2010-10-29 2016-01-12 Merck Sharp & Dohme Corp. Leucine-rich repeat kinase enzyme activity
WO2012118679A1 (en) 2011-02-28 2012-09-07 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2012135631A1 (en) 2011-03-30 2012-10-04 Arrien Pharmaeuticals Llc Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
EP2699572B1 (en) * 2011-04-21 2016-08-10 Origenis GmbH Heterocyclic compounds as kinase inhibitors
AU2012258977A1 (en) 2011-05-23 2014-01-16 Imago Pharmaceuticals, Inc. Inhibitors of LRRK2 kinase activity
CN102558174B (zh) * 2011-08-23 2014-03-19 天津市斯芬克司药物研发有限公司 一种全新吡唑并[4,3-c]吡啶化合物的发明及其合成方法
BR112014007654A8 (pt) * 2011-09-30 2018-06-12 Ipsen Pharma Inibidores de lrrk2 quinase macrocíclicos.
GB201204985D0 (en) 2012-03-21 2012-05-02 Genentech Inc Compounds
WO2013182612A1 (en) 2012-06-07 2013-12-12 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
WO2014001973A1 (en) * 2012-06-29 2014-01-03 Pfizer Inc. NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
WO2014026330A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
US10000482B2 (en) 2012-10-19 2018-06-19 Origenis Gmbh Kinase inhibitors
EP2914597B1 (en) * 2012-10-31 2017-12-06 RaQualia Pharma Inc Pyrazolopyridine derivatives as ttx-s blockers
MD20150037A2 (ro) * 2012-11-08 2015-11-30 Pfizer Inc. Compuşi heteroaromatici şi utilizarea lor ca liganzi de dopamină D1
EP2968995B1 (en) * 2013-03-15 2018-05-09 Elan Pharmaceuticals LLC Inhibitors of lrrk2 kinase activity
US9045477B2 (en) * 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201533043A (zh) * 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物
TW201534597A (zh) 2013-06-20 2015-09-16 Ab Science 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物
WO2015026683A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
CR20160525A (es) * 2014-05-14 2016-12-20 Pfizer Pirazolopiridinas y pirazolopirimidinas
WO2016036586A1 (en) * 2014-09-03 2016-03-10 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
KR102161364B1 (ko) 2015-09-14 2020-09-29 화이자 인코포레이티드 LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
WO2017215600A1 (en) 2016-06-15 2017-12-21 Suzhou Yabao Pharmaceutical R&D Co., Ltd. Substituted tricyclic herteocyclic compounds and use thereof
KR101923852B1 (ko) 2017-02-24 2018-11-29 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
KR101990738B1 (ko) * 2018-07-24 2019-06-19 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
AU2020395783A1 (en) * 2019-12-04 2022-06-09 Arcus Biosciences, Inc. Inhibitors of HIF-2alpha
CR20220644A (es) 2020-06-22 2023-02-17 Hoffmann La Roche Derivados de sulfona
MX2023002224A (es) * 2020-09-03 2023-03-15 Hoffmann La Roche Compuestos heterociclicos.
AU2023225858B2 (en) * 2022-02-25 2026-03-19 Suzhou Yabao Pharmaceutical R & D Co., Ltd. Substituted fused ring compound, pharmaceutical composition thereof, preparation method therefor and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017062A1 (en) 1993-01-28 1994-08-04 Zeneca Limited Substituted fused pyrazolo compounds and their use as herbicides
WO2006077319A1 (fr) 2005-01-19 2006-07-27 Aventis Pharma S.A. Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3835144A (en) * 1972-06-16 1974-09-10 Squibb & Sons Inc Amino derivatives of (4,3-c pyrazolopyridine cabroxylic acids and esters
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US5478830A (en) * 1992-05-29 1995-12-26 The Du Pont Merck Pharmaceutical Company Fused-ring heterocycles for the treatment of atherosclerosis
CA2482838A1 (en) * 2002-05-31 2003-12-11 Eisai Co., Ltd. Pyrazole compounds and pharmaceutical compositions containing the compound
EP1545515A1 (en) * 2002-08-12 2005-06-29 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
US7348338B2 (en) * 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
EP1653946A4 (en) * 2003-08-06 2007-04-04 Sugen Inc 3-CYCLOPENTYLIDENE-1,3-DIHYDROINDOL-2-ONES GEOMETRICALLY LIMITED AS POWERFUL INHIBITORS OF PROTEIN KINASES
WO2005121094A1 (en) * 2004-06-09 2005-12-22 Pfizer Limited Piperazine and piperidine derivatives as anti-hiv-agents
WO2006009245A1 (ja) * 2004-07-23 2006-01-26 Tanabe Seiyaku Co., Ltd. 含窒素縮合二環式化合物
US7553639B2 (en) * 2006-01-31 2009-06-30 Elan Pharma International Limited Alpha-synuclein kinase
CA2647543A1 (en) * 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
EP2346868B1 (en) * 2008-09-26 2016-01-27 Boehringer Ingelheim International Gmbh Azaindazole compounds as ccr1 receptor antagonists
GB201015949D0 (en) * 2010-09-22 2010-11-03 Medical Res Council Technology Compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017062A1 (en) 1993-01-28 1994-08-04 Zeneca Limited Substituted fused pyrazolo compounds and their use as herbicides
WO2006077319A1 (fr) 2005-01-19 2006-07-27 Aventis Pharma S.A. Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation

Also Published As

Publication number Publication date
WO2010106333A1 (en) 2010-09-23
PE20120506A1 (es) 2012-05-14
IL215147A0 (en) 2011-12-29
EP2408772B1 (en) 2015-07-01
CN102428084A (zh) 2012-04-25
CA2754605A1 (en) 2010-09-23
AU2010224693A1 (en) 2011-09-15
JP2012520861A (ja) 2012-09-10
JP5732036B2 (ja) 2015-06-10
RU2011142182A (ru) 2013-04-27
CA2754605C (en) 2018-04-17
CL2011002267A1 (es) 2012-05-11
EP2408772A1 (en) 2012-01-25
KR20110128925A (ko) 2011-11-30
AU2010224693B2 (en) 2016-07-28
US20170320870A1 (en) 2017-11-09
MX2011009807A (es) 2011-09-29
CN102428084B (zh) 2016-05-18
US20100317646A1 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
KR101700229B1 (ko) 화합물들
US8569281B2 (en) Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK
EP2091951B1 (en) Pyrido[2,3-b]pyrazine and [1,8]-naphthyridine derivatives as alk and c-met inhibitors
CN1946725B (zh) 用作细胞周期蛋白依赖激酶抑制剂的新型吡唑并嘧啶
EP3190889B1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
JP6157455B2 (ja) 含窒素複素環化合物
EP2964220B1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
JP2013529196A (ja) キナーゼｌｒｒｋ２の阻害剤としてのピラゾロピリジン
EP3068389B1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
AU2006297948A1 (en) Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
CA2931249A1 (en) Pyrrolopyrrolone derivatives and their use as bet inhibitors
CN102408429A (zh) 抑制醛甾酮合酶和芳香酶的稠合咪唑并衍生物
HUE035612T2 (en) 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
BR112020021569A2 (pt) Inibidor da interação proteína-proteína mll1-wdr5 de fenil triazol
CN106795152B (zh) 蛋白激酶抑制剂
CN109071558B (zh) 取代的三环杂环化合物及其用途
TWI613200B (zh) 含氮雜環化合物
HK40105557B (zh) Tyk2抑制剂及其用途
HK40105557A (zh) Tyk2抑制剂及其用途
TW201910325A (zh) 吲哚衍生物及其用途
HK1260037A1 (en) Substituted tricyclic herteocyclic compounds and use thereof
HK1260037B (zh) 取代的三环杂环化合物及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200121

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200121